ArticleJournal of pharmacokinetics and pharmacodynamics2014
Monoclonal antibody disposition: a simplified PBPK model and its implications for the derivation and interpretation of classical compartment models.
Article in Journal of pharmacokinetics and pharmacodynamics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- A new pharmacokinetic model forScientific reports · 2018Trial
- Quantitative Investigation of ATP Switch Concept of STA551 Through Combined In Vivo Tissue Distribution Studies and Physiologically Based Pharmacokinetic Modeling.The AAPS journal · 2026Article
- Tackling High Dimensionality in QSP: Guiding Model Order Reduction With Index Analysis.CPT: pharmacometrics & systems pharmacology · 2026Article
- Article
- Immunoglobulin G Receptors (FcγR), in Addition to Target-Antigen and Neonatal Fc Receptor (FcRn), Influence Rituximab Pharmacokinetics.Clinical pharmacokinetics · 2025Article
- Investigation of simplified physiologically-based pharmacokinetic models in rat and human.CPT: pharmacometrics & systems pharmacology · 2023Article
- Localization of drug biodistribution in a 3D-bioengineered subcutaneous neovascularized microenvironment.Materials today. Bio · 2022Article
- Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection.International journal of molecular sciences · 2022Review
- Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1.The AAPS journal · 2022Article
- Investigating brain uptake of a non-targeting monoclonal antibody after intravenous and intracerebroventricular administration.Frontiers in pharmacology · 2022Article
- Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid.Pharmaceutics · 2021Article
- Improving priors for human monoclonal antibody linear pharmacokinetic parameters by using half-lives from non-human primates.Journal of pharmacokinetics and pharmacodynamics · 2021Article
- Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications.Clinical pharmacokinetics · 2020Review
- Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans.Clinical pharmacokinetics · 2019Review
- Parameter Identification for a Model of Neonatal Fc Receptor-Mediated Recycling of Endogenous Immunoglobulin G in Humans.Frontiers in immunology · 2019Article
- MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues.Journal of pharmacokinetics and pharmacodynamics · 2018Article
- Benchmarking QSP Models Against Simple Models: A Path to Improved Comprehension and Predictive Performance.CPT: pharmacometrics & systems pharmacology · 2018Article
- Model reduction in mathematical pharmacology : Integration, reduction and linking of PBPK and systems biology models.Journal of pharmacokinetics and pharmacodynamics · 2018Article
- Article
- A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim.Journal of pharmacokinetics and pharmacodynamics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The structure, interpretation and parameterization of classical compartment models as well as physiologically-based pharmacokinetic (PBPK) models for monoclonal antibody (mAb) disposition are very diverse, with no apparent consensus. In addition, there is a remarkable discrepancy between the simplicity of experimental plasma and tissue profiles and the complexity of published PBPK models. We present a simplified PBPK model based on an extravasation rate-limited tissue model with elimination potentially occurring from various tissues and plasma. Based on model reduction (lumping), we derive several classical compartment model structures that are consistent with the simplified PBPK model and experimental data. We show that a common interpretation of classical two-compartment models for mAb disposition-identifying the central compartment with the total plasma volume and the peripheral compartment with the interstitial space (or part of it)-is not consistent with current knowledge. Results are illustrated for the monoclonal antibodies 7E3 and T84.66 in mice.
Indexed as
Identifiers
24493102What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.